CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- 8-K Event Material agreement · Regulation FD disclosure
- 4 Open-market sale See Remarks sold 4,000 shares at $12.40 ($49,600)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale Chief Development Officer sold 1,385 shares at $15.01 ($20,789)
- 4 Open-market sale 10% owner sold 49,910 shares at an average $14.26 ($711,676)
- 4 Open-market sale Chief Development Officer sold 8,000 shares at $14.51 ($116,080)
- 4 Open-market sale Acting Chief Business Officer sold 20,000 shares at an average $15.18 ($303,593)
- 4 Open-market sale Acting Chief Business Officer sold 40,000 shares at an average $13.33 ($533,304)
- 4 Grant or award Chief Development Officer acquired 1,620 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 1,451 shares (grant or award)
- 4 Grant or award President and CEO acquired 1,620 shares (grant or award)
- 4 Option exercise 10% owner acquired 140,374 shares (option exercise)
Page 16 of 24 · 471 filings